172 related articles for article (PubMed ID: 37116859)
21. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.
Mollaoglu G; Guthrie MR; Böhm S; Brägelmann J; Can I; Ballieu PM; Marx A; George J; Heinen C; Chalishazar MD; Cheng H; Ireland AS; Denning KE; Mukhopadhyay A; Vahrenkamp JM; Berrett KC; Mosbruger TL; Wang J; Kohan JL; Salama ME; Witt BL; Peifer M; Thomas RK; Gertz J; Johnson JE; Gazdar AF; Wechsler-Reya RJ; Sos ML; Oliver TG
Cancer Cell; 2017 Feb; 31(2):270-285. PubMed ID: 28089889
[TBL] [Abstract][Full Text] [Related]
22. Expression of p64c-myc and neuroendocrine properties define three subclasses of small cell lung cancer.
Bepler G; Bading H; Heimann B; Kiefer P; Havemann K; Moelling K
Oncogene; 1989 Jan; 4(1):45-50. PubMed ID: 2536917
[TBL] [Abstract][Full Text] [Related]
23. MYC drives platinum resistant SCLC that is overcome by the dual PI3K-HDAC inhibitor fimepinostat.
Chen J; Guanizo AC; Jakasekara WSN; Inampudi C; Luong Q; Garama DJ; Alamgeer M; Thakur N; DeVeer M; Ganju V; Watkins DN; Cain JE; Gough DJ
J Exp Clin Cancer Res; 2023 Apr; 42(1):100. PubMed ID: 37098540
[TBL] [Abstract][Full Text] [Related]
24. MAX mutant small-cell lung cancers exhibit impaired activities of MGA-dependent noncanonical polycomb repressive complex.
Llabata P; Torres-Diz M; Gomez A; Tomas-Daza L; Romero OA; Grego-Bessa J; Llinas-Arias P; Valencia A; Esteller M; Javierre BM; Zhang X; Sanchez-Cespedes M
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34493659
[TBL] [Abstract][Full Text] [Related]
25. Human small-cell lung cancers show amplification and expression of the N-myc gene.
Nau MM; Brooks BJ; Carney DN; Gazdar AF; Battey JF; Sausville EA; Minna JD
Proc Natl Acad Sci U S A; 1986 Feb; 83(4):1092-6. PubMed ID: 2869482
[TBL] [Abstract][Full Text] [Related]
26. Bromodomain and hedgehog pathway targets in small cell lung cancer.
Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
[TBL] [Abstract][Full Text] [Related]
27. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
Tokgun O; Tokgun PE; Inci K; Akca H
Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
[TBL] [Abstract][Full Text] [Related]
28. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.
Zhou Z; Patel M; Ng N; Hsieh MH; Orth AP; Walker JR; Batalov S; Harris JL; Liu J
BMC Cancer; 2014 Dec; 14():944. PubMed ID: 25495526
[TBL] [Abstract][Full Text] [Related]
29. Array-CGH reveals recurrent genomic changes in Merkel cell carcinoma including amplification of L-Myc.
Paulson KG; Lemos BD; Feng B; Jaimes N; Peñas PF; Bi X; Maher E; Cohen L; Leonard JH; Granter SR; Chin L; Nghiem P
J Invest Dermatol; 2009 Jun; 129(6):1547-55. PubMed ID: 19020549
[TBL] [Abstract][Full Text] [Related]
30. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
[TBL] [Abstract][Full Text] [Related]
31. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.
Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F
Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis.
Umemura S; Mimaki S; Makinoshima H; Tada S; Ishii G; Ohmatsu H; Niho S; Yoh K; Matsumoto S; Takahashi A; Morise M; Nakamura Y; Ochiai A; Nagai K; Iwakawa R; Kohno T; Yokota J; Ohe Y; Esumi H; Tsuchihara K; Goto K
J Thorac Oncol; 2014 Sep; 9(9):1324-31. PubMed ID: 25122428
[TBL] [Abstract][Full Text] [Related]
33. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer.
Nau MM; Brooks BJ; Battey J; Sausville E; Gazdar AF; Kirsch IR; McBride OW; Bertness V; Hollis GF; Minna JD
Nature; 1985 Nov 7-13; 318(6041):69-73. PubMed ID: 2997622
[TBL] [Abstract][Full Text] [Related]
34. MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.
Dammert MA; Brägelmann J; Olsen RR; Böhm S; Monhasery N; Whitney CP; Chalishazar MD; Tumbrink HL; Guthrie MR; Klein S; Ireland AS; Ryan J; Schmitt A; Marx A; Ozretić L; Castiglione R; Lorenz C; Jachimowicz RD; Wolf E; Thomas RK; Poirier JT; Büttner R; Sen T; Byers LA; Reinhardt HC; Letai A; Oliver TG; Sos ML
Nat Commun; 2019 Aug; 10(1):3485. PubMed ID: 31375684
[TBL] [Abstract][Full Text] [Related]
35. Myc manipulates the miRNA content and biologic functions of small cell lung cancer cell-derived small extracellular vesicles.
Tokgün O; İnci K
Mol Biol Rep; 2022 Aug; 49(8):7953-7965. PubMed ID: 35690961
[TBL] [Abstract][Full Text] [Related]
36. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.
Voortman J; Lee JH; Killian JK; Suuriniemi M; Wang Y; Lucchi M; Smith WI; Meltzer P; Wang Y; Giaccone G
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13040-5. PubMed ID: 20615970
[TBL] [Abstract][Full Text] [Related]
37. Target Identification in Small Cell Lung Cancer via Integrated Phenotypic Screening and Activity-Based Protein Profiling.
Li J; Fang B; Kinose F; Bai Y; Kim JY; Chen YA; Rix U; Koomen JM; Haura EB
Mol Cancer Ther; 2016 Feb; 15(2):334-42. PubMed ID: 26772203
[TBL] [Abstract][Full Text] [Related]
38. Lineage-restricted neoplasia driven by Myc defaults to small cell lung cancer when combined with loss of p53 and Rb in the airway epithelium.
Chen J; Guanizo A; Luong Q; Jayasekara WSN; Jayasinghe D; Inampudi C; Szczepny A; Garama DJ; Russell PA; Ganju V; Cain JE; Watkins DN; Gough DJ
Oncogene; 2022 Jan; 41(1):138-145. PubMed ID: 34675406
[TBL] [Abstract][Full Text] [Related]
39. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
[TBL] [Abstract][Full Text] [Related]
40. Different pattern of expression of cellular oncogenes in human non-small-cell lung cancer cell lines.
Kiefer PE; Wegmann B; Bacher M; Erbil C; Heidtmann H; Havemann K
J Cancer Res Clin Oncol; 1990; 116(1):29-37. PubMed ID: 1690210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
